Cell Care Therapeutics

Cell Care Therapeutics is a United States-based startup that is focused on developing a new class of biologics derived from the secreted proteins and exosomes of mesenchymal stromal cells (MSCs). The company's novel secretome platform leverages the signaling molecules of MSCs to promote the health of blood vessels and their surrounding tissue. Their flagship product in development targets the treatment of diabetic macular edema, which is the leading cause of vision loss in working-age adults. This innovative approach has captured the attention of venture capital firms, positioning Cell Care Therapeutics as a promising player in the biotech industry. With its potential to address a significant unmet medical need, the company's cutting-edge technology holds promise for both patients and investors.